DOX Quote, Financials, Valuation and Earnings

CSP has a net margin of 13.62% compared to Amdocs's net margin of 3.01%. Amdocs's return on equity of 13.99% beat CSP's return on equity of 0.46%.

Amdocs has a consensus price target of $101.61, signalling upside risk potential of 22.01%. On the other hand CSP has an analysts' consensus of -- which suggests that it could fall by --. Given that Amdocs has higher upside potential than CSP, analysts believe Amdocs is more attractive than CSP.

Amdocs has a beta of 0.586, which suggesting that the stock is 41.422% less volatile than S&P 500. In comparison CSP has a beta of 1.220, suggesting its more volatile than the S&P 500 by 21.961%.

Amdocs has a quarterly dividend of $0.53 per share corresponding to a yield of 2.36%. CSP offers a yield of 0.79% to investors and pays a quarterly dividend of $0.03 per share. Amdocs pays 42.98% of its earnings as a dividend. CSP pays out -312.27% of its earnings as a dividend. Amdocs's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amdocs quarterly revenues are $1.1B, which are larger than CSP quarterly revenues of $15.7M. Amdocs's net income of $151.1M is higher than CSP's net income of $472K. Notably, Amdocs's price-to-earnings ratio is 19.32x while CSP's PE ratio is 1,516.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amdocs is 1.93x versus 2.55x for CSP. Usually stocks with elevated PS ratios are considered overvalued.

Intellinetics has a net margin of 13.62% compared to Amdocs's net margin of -1.26%. Amdocs's return on equity of 13.99% beat Intellinetics's return on equity of -5.34%.

Amdocs has a consensus price target of $101.61, signalling upside risk potential of 22.01%. On the other hand Intellinetics has an analysts' consensus of $17.50 which suggests that it could grow by 34.62%. Given that Intellinetics has higher upside potential than Amdocs, analysts believe Intellinetics is more attractive than Amdocs.

Amdocs has a beta of 0.586, which suggesting that the stock is 41.422% less volatile than S&P 500. In comparison Intellinetics has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.332%.

Amdocs has a quarterly dividend of $0.53 per share corresponding to a yield of 2.36%. Intellinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amdocs pays 42.98% of its earnings as a dividend. Intellinetics pays out -- of its earnings as a dividend. Amdocs's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amdocs quarterly revenues are $1.1B, which are larger than Intellinetics quarterly revenues of $4.3M. Amdocs's net income of $151.1M is higher than Intellinetics's net income of -$53.7K. Notably, Amdocs's price-to-earnings ratio is 19.32x while Intellinetics's PE ratio is 248.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amdocs is 1.93x versus 3.12x for Intellinetics. Usually stocks with elevated PS ratios are considered overvalued.

Signing Day Sports has a net margin of 13.62% compared to Amdocs's net margin of -2893.73%. Amdocs's return on equity of 13.99% beat Signing Day Sports's return on equity of --.

Amdocs has a consensus price target of $101.61, signalling upside risk potential of 22.01%. On the other hand Signing Day Sports has an analysts' consensus of -- which suggests that it could fall by --. Given that Amdocs has higher upside potential than Signing Day Sports, analysts believe Amdocs is more attractive than Signing Day Sports.

Amdocs has a beta of 0.586, which suggesting that the stock is 41.422% less volatile than S&P 500. In comparison Signing Day Sports has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Amdocs has a quarterly dividend of $0.53 per share corresponding to a yield of 2.36%. Signing Day Sports offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amdocs pays 42.98% of its earnings as a dividend. Signing Day Sports pays out -- of its earnings as a dividend. Amdocs's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amdocs quarterly revenues are $1.1B, which are larger than Signing Day Sports quarterly revenues of $55.4K. Amdocs's net income of $151.1M is higher than Signing Day Sports's net income of -$1.6M. Notably, Amdocs's price-to-earnings ratio is 19.32x while Signing Day Sports's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amdocs is 1.93x versus 0.58x for Signing Day Sports. Usually stocks with elevated PS ratios are considered overvalued.

WidePoint has a net margin of 13.62% compared to Amdocs's net margin of -1.23%. Amdocs's return on equity of 13.99% beat WidePoint's return on equity of -20.12%.

Amdocs has a consensus price target of $101.61, signalling upside risk potential of 22.01%. On the other hand WidePoint has an analysts' consensus of $6.50 which suggests that it could grow by 147.15%. Given that WidePoint has higher upside potential than Amdocs, analysts believe WidePoint is more attractive than Amdocs.

Amdocs has a beta of 0.586, which suggesting that the stock is 41.422% less volatile than S&P 500. In comparison WidePoint has a beta of 1.832, suggesting its more volatile than the S&P 500 by 83.194%.

Amdocs has a quarterly dividend of $0.53 per share corresponding to a yield of 2.36%. WidePoint offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amdocs pays 42.98% of its earnings as a dividend. WidePoint pays out -- of its earnings as a dividend. Amdocs's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amdocs quarterly revenues are $1.1B, which are larger than WidePoint quarterly revenues of $34.6M. Amdocs's net income of $151.1M is higher than WidePoint's net income of -$425.2K. Notably, Amdocs's price-to-earnings ratio is 19.32x while WidePoint's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amdocs is 1.93x versus 0.18x for WidePoint. Usually stocks with elevated PS ratios are considered overvalued.